[Formoterol-budesonide combination for maintenance and relief in children and adolescents with asthma].

International guidelines have been edited to standardize asthma management. These guidelines are often difficult to translate to clinical practice because of gaps in the knowledge of clinical practitioners but also because of compliance issues, particularly in children and adolescents. A new approach named SIT (for Single Inhaler Therapy) or SMART (for Symbicort Maintenance and Reliever Therapy) has demonstrated its safety and efficacy in numerous studies of adults with asthma summarized in two Cochrane reviews.

Montelukast does not prevent reactive airway disease in young children hospitalized for RSV bronchiolitis.

Aim: To evaluate the long-term effect of montelukast on symptoms of cough and wheeze following RSV bronchiolitis.

Methods: Fifty eight patients (aged < or = 24 months) hospitalized with a first episode of RSV bronchiolitis were enrolled in this double blind prospective randomized trial comparing montelukast (n = 31) vs placebo (n = 27).

Results: During the 3-month treatment period, there were no statistical significant differences between the two groups for symptom-free days and nights (48.

Early skin sensitization to aeroallergens.

Background: Early detection of aeroallergen sensitization is important as a prognosis factor but may be more difficult in young children.

Objective: We sought to demonstrate that skin sensitization to aeroallergens was present in a selected group of 0-2-year-old children and that it was associated with environmental exposure and a family history of allergic disease.

Methods: Data on exposure and history were extracted from the files of 824 children seen in the asthma clinic and who were skin tested to a panel of aero- and food allergens.